DarioHealth (NASDAQ:DRIO) Stock Rating Upgraded by Wall Street Zen

DarioHealth (NASDAQ:DRIO) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday.

DRIO has been the topic of several other research reports. Cowen reiterated a “hold” rating on shares of DarioHealth in a research note on Friday, November 14th. Stifel Nicolaus set a $16.00 price objective on shares of DarioHealth in a research report on Friday, November 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of DarioHealth in a research note on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, DarioHealth currently has an average rating of “Hold” and an average target price of $32.00.

DarioHealth Trading Up 1.8%

Shares of NASDAQ:DRIO opened at $12.44 on Friday. The company has a market capitalization of $84.09 million, a PE ratio of -1.11 and a beta of 1.05. The company has a current ratio of 4.55, a quick ratio of 4.02 and a debt-to-equity ratio of 0.41. DarioHealth has a 12-month low of $5.93 and a 12-month high of $17.74. The business’s fifty day simple moving average is $11.95 and its 200-day simple moving average is $12.05.

Institutional Trading of DarioHealth

A hedge fund recently raised its stake in DarioHealth stock. XTX Topco Ltd grew its stake in DarioHealth Corp. (NASDAQ:DRIO) by 229.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 62,511 shares of the company’s stock after buying an additional 43,513 shares during the period. XTX Topco Ltd owned 0.14% of DarioHealth worth $42,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 33.39% of the company’s stock.

DarioHealth Company Profile

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.